查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602795

抗肥胖藥物市場：依藥物類型、作用機轉分類 - 全球預測 2025-2030

Anti-Obesity Drugs Market by Drug Type (Over-The-Counter Drugs, Prescription Drugs), Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

根據預測，2023年抗肥胖藥物市值為38.3億美元，預計到2024年將達到40.9億美元，複合年成長率為6.86%，到2030年將達到61億美元。

抗肥胖藥物市場範圍包括旨在透過降低食慾、增加飽足感和抑制營養吸收來促進減肥的藥物。隨著全球肥胖率的迅速上升，有效的藥物干預措施至關重要，不僅對於體重管理，而且對於降低糖尿病、心血管疾病和某些癌症等相關健康風險也變得非常重要。最終用途範圍從醫療保健提供者和醫院到零售藥房和研究機構。

主要市場統計
基準年[2023] 38.3億美元
預測年份 [2024] 40.9億美元
預測年份 [2030] 61億美元
複合年成長率（%） 6.86%

該市場的主要成長要素是人們對肥胖相關健康風險的認知不斷提高、藥物開發的技術進步以及政府倡導肥胖管理的支持政策。世界上越來越多的久坐生活方式和不健康的飲食模式進一步增加了對有效肥胖控制解決方案的需求。該領域的潛在機會包括根據基因圖譜客製化治療的個人化醫療方法以及探索聯合治療以提高藥物療效。公司可以透過投資研發來開發更強大、副作用更少的藥物並擴大其地理覆蓋範圍，特別是在肥胖率上升的新興經濟體，從而增強其市場地位。

市場開拓的挑戰包括嚴格的監管核准、高昂的藥物開發成本、潛在的藥物副作用以及對肥胖治療的社會恥辱。此外，由於大眾對生活方式和手術治療的偏好，對藥物干預的懷疑限制了市場滲透。創新應著重於開發胰島素增敏劑、針對腸道微生物群的藥物，以及數位健康技術與藥物治療方案結合的機會，以提高患者的依從性和治療結果。為了持續成長，為了強調綜合治療計劃的重要性，強調藥物有效性的現實證據，並消除公眾對藥物安全性和有效性的誤解，公司應該鼓勵與醫療保健提供者合作。市場仍然競爭激烈，要求公司透過策略夥伴關係和以患者為中心的創新不斷發展。

市場動態：揭示快速發展的抗肥胖藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗肥胖藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 肥胖和相關慢性疾病的負擔增加
    • 不健康的速食和家常小菜的消費量迅速增加
    • 增強健康意識
  • 市場限制因素
    • 與藥物相關的副作用
  • 市場機會
    • 提高人們對聯合策略的認知
    • 減肥藥的最新進展
  • 市場挑戰
    • 市場上替代治療方案的可用性

波特五力：駕馭抗肥胖藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗肥胖藥物市場的外部影響

外部宏觀環境因素在塑造抗肥胖藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗肥胖藥物市場的競爭狀況

抗肥胖藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗肥胖藥物市場供應商績效評估

FPNV定位矩陣是評估抗肥胖藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了抗肥胖藥物市場的成功之路

抗肥胖藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肥胖和相關慢性疾病的負擔日益增加
      • 快速食用不健康的速食和即食食品
      • 人們對健康和健身的興趣日益濃厚
    • 抑制因素
      • 與藥物相關的副作用
    • 機會
      • 對協作策略的認知不斷增強
      • 肥胖症藥物治療的最新進展
    • 任務
      • 市場上替代治療方案的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按類型分類的抗肥胖藥物市場

  • 非處方藥
  • 處方藥

第7章依作用機轉分類的抗肥胖藥物市場

  • 中樞促效劑
  • 周邊促效劑

第8章 北美和南美抗肥胖藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗肥胖藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲抗肥胖藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.09 billion in 2024, and is projected to grow at a CAGR of 6.86%, to USD 6.10 billion by 2030.

The scope of the anti-obesity drugs market encompasses pharmaceuticals designed to facilitate weight loss by reducing appetite, increasing satiety, or inhibiting nutrient absorption. With global obesity rates soaring, the necessity for effective pharmacological interventions has become critical, not only to manage weight but also to mitigate associated health risks like diabetes, cardiovascular diseases, and certain cancers. The primary applications include chronic weight management for patients with a significant body mass index (BMI), and the end-use scope ranges from healthcare providers and hospitals to retail pharmacies and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 3.83 billion
Estimated Year [2024] USD 4.09 billion
Forecast Year [2030] USD 6.10 billion
CAGR (%) 6.86%

Key growth factors in this market are driven by the increasing awareness of health risks linked to obesity, technological advancements in drug development, and supportive governmental policies advocating for obesity management. The rise in sedentary lifestyles and unhealthy diet patterns worldwide further escalates the need for effective anti-obesity solutions. Potential opportunities in this sector include personalized medicine approaches that tailor treatments based on genetic profiles and the exploration of combination therapies to enhance drug efficacy. Companies can strengthen their market position by investing in R&D to develop more potent drugs with fewer side effects and by expanding their geographical reach, especially in emerging economies where obesity rates are climbing.

Challenges impeding market growth consist of stringent regulatory approvals, high costs of drug development, potential side effects of medications, and societal stigma linked to obesity treatments. Moreover, market penetration is limited by public skepticism towards pharmacological interventions due to the preference for lifestyle and surgical treatments. Innovations should focus on developing insulin sensitizers, gut microbiota-targeting drugs, and opportunities for digital health technologies that integrate with drug regimens to improve patient adherence and outcomes. For sustained growth, businesses should foster collaborations with healthcare providers to emphasize the importance of comprehensive treatment plans, highlight real-world evidence of drug effectiveness, and address public misconceptions about medication safety and efficacy. The market's nature remains highly competitive, requiring firms to continuously evolve through strategic partnerships and patient-centric innovations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Drugs Market

The Anti-Obesity Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of obesity and related chronic diseases
    • Rapid consumption of unhealthy fast-foods and ready meals
    • Increasing inclination towards health & fitness
  • Market Restraints
    • Side-effects associated with drugs
  • Market Opportunities
    • Growing awareness among people with collaborative strategies
    • Recent advancements in drug treatment of obesity
  • Market Challenges
    • Availability of alternative treatment options in market

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Drugs Market

A detailed market share analysis in the Anti-Obesity Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Drugs Market

A strategic analysis of the Anti-Obesity Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Drugs Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus Inc..

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.
  • Based on Mechanism of Action, market is studied across Centrally Acting Drugs and Peripherally Acting Drugs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of obesity and related chronic diseases
      • 5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
      • 5.1.1.3. Increasing inclination towards health & fitness
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing awareness among people with collaborative strategies
      • 5.1.3.2. Recent advancements in drug treatment of obesity
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options in market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Obesity Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Drugs
  • 6.3. Prescription Drugs

7. Anti-Obesity Drugs Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Centrally Acting Drugs
  • 7.3. Peripherally Acting Drugs

8. Americas Anti-Obesity Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Boehringer Ingelheim International GmbH
  • 3. Bristol-Myers Squibb Company
  • 4. Currax Pharmaceuticals LLC
  • 5. Eisai Co. Ltd
  • 6. F. Hoffmann-La Roche AG
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co. Inc.
  • 9. Norgine BV
  • 10. Novo Nordisk AS
  • 11. Pfizer Inc.
  • 12. Rhythm Pharmaceuticals, Inc.
  • 13. SHIONOGI & Co., Ltd.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Vivus Inc.

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CENTRALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023